Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial

Annals of Oncology

Volumn 17, Issue 8, 2006, Pages 1221-1227

  Roche H ^a   Kerbrat, P ^b   Bonneterre, J ^c   Fargeot, P ^d   Fumoleau, P ^d   Monnier, A ^e   Clavere P ^f   Goudier, M J ^g   Chollet, P ^h   Guastalla, J P ⁱ   Serin, D ^j  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e Centre Hospitalier André Boulloche   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g Centre Hospitalier de Bretagne Sud   (France)

^h CENTRE JEAN PERRIN   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

^j INSTITUT SAINTE CATHERINE   (France)

more..

Author keywords

Breast cancer; Epirubicin; Hormonal blockade; Hormone receptor positive; Node positive; Premenopausal

Indexed keywords

ANTIEMETIC AGENT; BILIRUBIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIPTORELIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; FRANCE; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HORMONE INHIBITION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SKIN CARCINOMA; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33747885300     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl107     Document Type: Article

References (29)

1. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-906.
2. Fisher B, Cardone P, Economou SG et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 1975; 292: 117-122.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
4. Misset JL, di Palma M, Delgado M et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14: 1136-1145.
5. Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin -based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298-305.
6. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985; 1: 836-840.
7. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996; 348: 1189-1196.
8. Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353.
9. Klijn JG, Beex LV, Mauriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 2000; 92: 903-911.
10. Jonat W, Kaufmann M, Blamey RW et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer, Eur J Cancer 1995; 31A: 137-142.
11. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 1993; 341: 1293-1298.
12. Ejlertsen B, Dombernowsky P, Mouridsen HT et al. Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proc Am Soc Clin Oncol 1999; 18: 248 (Abstr).
13. Boccardo F, Rubagotti A, Amoroso D et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 1992; 28: 673-680.
14. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
15. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 2002; 20: 4621-4627.
16. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
17. Snedecor GW, Cochran WG. Statistical Methods, 7th edition. Ames: Iowa State University Press 1980.
18. Duncan DB. P-tests and intervals for comparison suggested by the data. Biometrics 1975; 31: 339-359.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-202.
21. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
22. Bonneterre J, Roche H, Kerbrat P et al, Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23: 2686-2693.
23. Boccardo F, Rubagotti A, Amoroso D et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000; 18: 2718-2727.
24. Castiglione-Gertsch M, O'Neill A, Price KN et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
25. Roche H, Mihura J, de Lafontan B et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: A randomized trial with a 7 years median follow-up. Proc Am Soc Clin Oncol 1996; 15: 117 (Abstr).
26. Davidson N, O'Neill A, Vukov A et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 1999; 18: 249 (Abstr).
27. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1990; 1: 183-188.
28. Bianco AR, Del Mastro L, Gallo C et al. Prognostic role of amenorrhoea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991; 63: 799-803.
29. Pagani O, O'Neill A, Castiglione M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) trial VI. Eur J Cancer 1998; 34: 632-640.